Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBIT Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBIT Margin for 14 consecutive years, with 12.99% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 254.0% to 12.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 13.85% through Dec 2025, down 327.0% year-over-year, with the annual reading at 11.79% for FY2025, 935.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 12.99% at Aytu Biopharma, down from 10.83% in the prior quarter.
  • The five-year high for EBIT Margin was 44.43% in Q2 2023, with the low at 220.76% in Q1 2022.
  • Average EBIT Margin over 5 years is 35.7%, with a median of 12.99% recorded in 2025.
  • The sharpest move saw EBIT Margin plummeted -18031bps in 2021, then skyrocketed 18311bps in 2023.
  • Over 5 years, EBIT Margin stood at 48.84% in 2021, then soared by 46bps to 26.13% in 2022, then soared by 164bps to 16.78% in 2023, then tumbled by -162bps to 10.45% in 2024, then decreased by -24bps to 12.99% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 12.99%, 10.83%, and 50.37% for Q4 2025, Q3 2025, and Q2 2025 respectively.